Guillaume Canaud, ESMO 2021: EPIK-P1 Study of Alpelisib in the Treatment Patients With PIK3CA-related Overgrowth Spectrum

touchONCOLOGY joins Professor Guillaume Canaud (Necker–Enfants Malades Hospital, Paris, France), to discuss EPIK-P1, a retrospective chart review study of patients with PIK3CA-related overgrowth spectrum who have received alpelisib as part of a compassionate use programme.

Questions
1. Could you tell us a little about PIK3CA-related Overgrowth Spectrum (PROS), the clinical manifestations and prognosis? (00:25-01:11)
2. What is the rationale for the use of alpelisib in the treatment of patients with PROS? (01:11-01:44)
3. What were the aims, design and inclusion criteria of the EPIK-P1 study? (01:33-02:56)
4. What were the efficacy and safety findings of the study? (02:56-04:30)
5. What are the clinical implications of these findings, and what future studies are planned? (04:30-05:24)

Disclosures: TBC

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson

Filmed in coverage of the ESMO 2021 Annual Meeting.